Comparative efficacy of CRP changes at 12 weeks. The relative effect size is presented as mean difference with 95% CrI.
| Drug | ADA | CZP | ETN | GOL | IFX | IFX-dyyb | PBO |
|---|---|---|---|---|---|---|---|
| ADA | – | −0.45 (−1.5 to 0.6) | 0.2 (−0.6 to 1.0) | 0.01 (−0.9 to 0.9) | 0.4 (−0.5 to 1.4) | NA | −1.2 (−1.8 to −0.6) |
| CZP | 0.5 (−0.6 to 1.5) | – | 0.6 (−0.4 to 1.6) | 0.5 (−0.6 to 1.6) | 0.9 (−0.3 to 2) | NA | −0.7 (−1.6 to 0.2) |
| ETN | −0.2 (−0.9 to 0.6) | −0.6 (−1.6 to 0.4) | – | −0.2 (−1.0 to 0.7) | 0.2 (−0.6 to 1.1) | NA | −1.3 (−1.8 to −0.9) |
| GOL | −0.00 (−0.9 to 0.8) | −0.5 (−1.6 to 0.6) | 0.2 (−0.7 to 1.0) | – | 0.4 (−0.6 to 1.4) | NA | −1.2 (−1.8 to −0.6) |
| IFX | −0.4 (−1.4 to 0.5) | −0.9 (−2 to 0.3) | −0.2 (−1.1 to 0.6) | −0.4 (−1.4 to 0.6) | – | NA | −1.6 (−2.3 to −0.9) |
| IFX-dyyb | NA | NA | NA | NA | NA | – | NA |
| PBO | 1.2 (0.6–1.8) | 0.7 (−0.2 to 1.6) | 1.3 (0.9–1.8) | 1.2 (0.6–1.8) | 1.6 (0.9–2.3) | NA | – |
Values below the diagonal represent the analysis with 1 open-label trial. Values above the diagonal represent the analysis without the open-label trial. Each cell represents a paired comparison. The columns represent the reference medication for each comparison, and the rows represent the comparators. A negative value means greater improvement by the comparator, indicating the comparator is more efficacious than the reference drug. A positive value means less improvement by the comparator, indicating the reference drug is more efficacious than the comparator. Cells in bold are statistically significant comparisons at p < 0.05. BASDAI: Bath Ankylosing Spondylitis Disease Activity Score; BASFI: Bath Ankylosing Spondylitis Functional Index; CrI: credible interval; CRP: C-reactive protein; ADA: adalimumab; CZP: certolizumab; ETN: etanercept; GOL: golimumab; IFX: infliximab; IFX-dyyb: infliximab-dyyb (IFX biosimilar); PBO: placebo.